WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Thursday, January 13, 2005

Hide?	Set Name	Query	Hit Count
	DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=AND		
☐	L1	neri.in. and fibronectin	14
☐	L2	neri.in. and viti.in.	12
☐	L3	(oncofetal or onco-fetal) near10 fibronectin	56

END OF SEARCH HISTORY

Generate Collection | Print

Search Results - Record(s) 1 through 50 of 56 returned.

☐ 1. 20040266025. 06 Feb 04. 30 Dec 04. Screening and treatment methods for prevention of preterm delivery. Hickok, Durlin, et al. 436/518; G01N033/543.

☐ 2. 20040260072. 23 Jan 04. 23 Dec 04. Hydrophilic, thiol-reactive cyanine dyes and conjugates thereof with biomolecules for fluorescence diagnosis. Licha, Kai, et al. 530/409; 548/156 548/219 548/453 C07K014/47 C07D417/02 C07D413/02 C07D43/02.

☐ 3. 20040258747. 26 May 04. 23 Dec 04. Tumor-targeted drug delivery systems and uses thereof. Ponzoni, Mirco, et al. 424/450; 424/93.2 A61K009/127 A61K048/00.

☐ 4. 20040241752. 25 Jun 04. 02 Dec 04. Point of care diagnostic systems. Anderson, Emory V., et al. 435/7.1; 702/19 G01N033/53 G06F019/00 G01N033/48 G01N033/50.

☐ 5. 20040230122. 14 Jun 04. 18 Nov 04. Ultrasound imaging. Eriksen, Morten, et al. 600/458; 424/9.51 A61B008/14.

☐ 6. 20040214247. 23 Apr 04. 28 Oct 04. Novel fibronectin epitopes and proteinaceous molecules capable of binding said epitopes. De Kruif, Cornelis Adriaan, et al. 435/7.23; 424/146.1 530/388.26 G01N033/574 A61K039/395 C07K016/40.

☐ 7. 20040180354. 05 Sep 03. 16 Sep 04. Epitope sequences. Simard, John J.L., et al. 435/6; 435/325 435/69.1 530/350 536/23.5 C12Q001/68 C07H021/04 C07K014/74.

☐ 8. 20040171123. 12 Apr 01. 02 Sep 04. ALBUMIN FUSION PROTEINS. Rosen, Craig A., et al. 435/69.7; 424/192.1 435/252.3 435/325 536/23.4 A61K038/00 C12P021/04 A61K039/00 C07H021/04 C12N005/02 C12N005/00 C12N001/20.

☐ 9. 20040072261. 20 Jun 03. 15 Apr 04. Method for the diagnosis and differential diagnosis of neurological diseases. Kostanjevecki, Vesna, et al. 435/7.2; G01N033/53 G01N033/567.

☐ 10. 20030220239. 04 Apr 02. 27 Nov 03. Epitope sequences. Simard, John J. L., et al. 514/12; 435/226 435/320.1 435/325 435/6 435/69.1 435/7.23 514/44 702/19 C12Q001/68 G01N033/574 A61K048/00 A61K038/17.

☐ 11. 20030186850. 12 Nov 02. 02 Oct 03. Methods of modulating functions of polypeptide GalNAc-transferases and of screening test substances to find agents herefor, pharmaceutical compositions comprising such agents and the use of such agents for preparing medicaments. Clausen, Henrik, et al. 514/8; 514/54 A61K038/17 A61K031/739.

☐ 12. 20030103963. 08 Mar 02. 05 Jun 03. Uses of monoclonal antibody 8H9. Cheung, Nai-Kong V.. 424/130.1; 424/141.1 435/320.1 435/326 435/69.1 530/388.15 536/23.53 A61K039/395 C07H021/04 C07K016/40 C12N005/06.

☐ 13. 20030087318. 12 Sep 02. 08 May 03. Antibodies against an extracellular matrix complex and their use in the detection of cancer. Lallone, Roger L.. 435/7.23; 435/7.93 G01N033/574 G01N033/53 G01N033/537 G01N033/543.

☐ 14. 20030049689. 12 Jun 02. 13 Mar 03. Multifunctional polypeptides. Edwards, Cynthia, et al. 435/7.1; 435/325 435/69.1 435/7.2 435/7.23 G01N033/53 G01N033/567 G01N033/574 C12P021/02 C12N005/06.

☐ 15. 20030046714. 07 Mar 02. 06 Mar 03. Anti-neovasculature preparations for cancer. Simard, John J.L., et al. 800/3; 800/18 A01K067/027.

☐ 16. 20020110833. 20 Dec 01. 15 Aug 02. Methods to diagnose a required regulation of trophoblast invasion. Caniggia, Isabella, et al. 435/7.1; 424/145.1 514/12 G01N033/53 A61K039/395 A61K038/17.

☐ 17. 20020102264. 18 Oct 01. 01 Aug 02. Uses of monoclonal antibody 8H9. Cheung, Nai-Kong V.. 424/155.1; 424/178.1 435/326 530/389.1 A61K039/395 C07K016/46 C12N005/06.

☐ 18. 20020019016. 27 Jun 01. 14 Feb 02. Differential diagnosis of neurological diseases. Vanmechelen, Eugeen, et al. 435/7.21; G01N033/567.

☐ 19. 6811766. 20 Apr 00; 02 Nov 04. Ultrasound imaging with contrast agent targeted to microvasculature and a vasodilator drug. Eriksen; Morten, et al. 424/9.52; 424/9.5 600/458. A61B008/00.

☐ 20. 6749853. 14 Jan 00; 15 Jun 04. Combined methods and compositions for coagulation and tumor treatment. Thorpe; Philip E., et al. 424/182.1; 424/178.1 530/387.1 530/387.3. A61K039/42 A61K039/44 C07K016/00 C12P021/08.

☐ 21. 6670137. 27 Jun 01; 30 Dec 03. Differential diagnosis of neurological diseases. VanMechelen; Eugeen, et al. 435/7.1; 435/7.21 435/7.8 436/501 530/300 530/350 530/387.1. G01N033/53 G01N033/567 G01N033/566 C07K001/00.

☐ 22. 6451312. 20 Jul 99; 17 Sep 02. VEGF-gelonin for targeting the vasculature of solid tumors. Thorpe; Philip E.. 424/183.1; 424/185.1 424/192.1 530/399. A61K039/395 A61K039/00 C07K014/475.

☐ 23. 6436642. 19 Apr 00; 20 Aug 02. Method of classifying a thyroid carcinoma using differential gene expression. Gould-Rothberg; Bonnie E., et al. 435/6; 435/320.1 435/69.1. C12Q001/68 C12P021/06 C12N015/00.

☐ 24. 6394952. 20 Apr 98; 28 May 02. Point of care diagnostic systems. Anderson; Emory V., et al. 600/300; 435/4 436/814 600/304 600/310 600/351 600/573 600/584. A61B005/00.

☐ 25. 6376199. 21 Dec 99; 23 Apr 02. Methods to diagnose a required regulation of trophoblast invasion. Caniggia; Isabella, et al. 435/7.2; 424/139.1 424/143.1 424/145.1 435/6 435/7.1. G01N033/567 C12Q001/68 A61K039/395 A61K039/42.

☐ 26. 6375970. 07 Jul 99; 23 Apr 02. Methods and materials for preterm birth prevention. Bieniarz; Andre. 424/422; 424/78.08 428/500 524/916 604/48. A61F013/00.

☐ 27. 6267722. 03 Feb 98; 31 Jul 01. Point of care diagnostic systems. Anderson; Emory V., et al. 600/300; 435/4 436/811 436/814 600/304 600/310 600/345 600/573 600/584. A61B005/00.

☐ 28. D434153. 20 Apr 98; 21 Nov 00. Point of care analyte detector system. Anderson; Emory V.,

et al. D24/216; D24/232. 2401.

☐ 29. D432244. 20 Apr 98; 17 Oct 00. Device for encasing an assay test strip. Anderson; Emory V., et al. D24/223;. 2402.

☐ 30. 6096512. 11 Nov 97; 01 Aug 00. Cloned DNA encoding a UDP-GalNAc: Polypeptide, N-acetylgalactosaminyltransferase. Elhammer; Ake P., et al. 435/68.1; 435/440 435/455 435/471 435/476 435/70.1 435/71.1 435/71.2 435/72 435/74 435/97. C12N015/54 C12P021/00.

☐ 31. 6093399. 07 Jun 95; 25 Jul 00. Methods and compositions for the specific coagulation of vasculature. Thorpe; Philip E., et al. 424/182.1; 424/178.1 424/179.1 424/180.1 530/387.1 530/387.3 530/387.7 530/387.9 530/388.1 530/388.22 530/388.85 530/391.7 530/391.9. A61K039/395.

☐ 32. 6051230. 01 Jun 95; 18 Apr 00. Compositions for targeting the vasculature of solid tumors. Thorpe; Philip E., et al. 424/178.1; 424/179.1 424/180.1 424/181.1 424/182.1 424/183.1 530/387.1 530/387.7 530/388.1 530/388.2. A61K039/395 C07K016/00.

☐ 33. 6036955. 07 Jun 95; 14 Mar 00. Kits and methods for the specific coagulation of vasculature. Thorpe; Philip E., et al. 424/136.1; 424/130.1 424/141.1 424/143.1 424/144.1 424/145.1 424/152.1 424/155.1 424/156.1 424/158.1 424/178.1 424/85.2 514/8 530/387.3 530/387.7 530/388.7 530/389.6 530/389.7 530/391.7. A61K039/395.

☐ 34. 6027908. 07 Oct 96; 22 Feb 00. Method for differentiating vaginal secretory fluid or cervical mucus of pregnant woman suffering from threatened premature delivery. Saito; Shigeru, et al. 435/7.92; 435/7.1 436/501 436/518 436/531 436/811 436/815. G01N033/53.

☐ 35. 6004555. 07 Jun 95; 21 Dec 99. Methods for the specific coagulation of vasculature. Thorpe; Philip E., et al. 424/181.1; 424/178.1 424/180.1 435/7.23 530/381 530/382 530/383 530/384 530/391.7. A61K039/395 A61K035/14 C07K016/00 G01N033/574.

☐ 36. 6004554. 02 Dec 94; 21 Dec 99. Methods for targeting the vasculature of solid tumors. Thorpe; Philip E., et al. 424/178.1; 424/136.1 424/181.1 424/182.1 424/183.1. A61K039/395 A61K039/40 A61K039/42.

☐ 37. 5965132. 05 Dec 94; 12 Oct 99. Methods and compositions for targeting the vasculature of solid tumors. Thorpe; Philip E., et al. 424/1.49; 424/1.45 424/139.1 424/156.1 424/183.1 435/70.1 435/70.2 530/387.2 530/391.7 530/391.9 530/807 530/828. A61K051/00.

☐ 38. 5910570. 11 Nov 97; 08 Jun 99. Cloned DNA encoding a UDP-GalNAc: polypeptide N-acetylgalactosaminy-ltransferase. Elhammer; Ake P., et al. 530/328; 435/193. C07K007/06 C12N009/10.

☐ 39. 5871990. 15 May 96; 16 Feb 99. UDP-N-acetyl-.alpha.-D-galactosamine: polypeptide N-acetylgalactosaminyltransferase, gAlnAc-T3. Clausen; Henrik, et al. 435/193; 435/252.3 435/320.1 435/6 435/69.1 530/350 536/23.2 536/24.3 536/24.31. C12N009/10 C12N001/20 C12P021/06 C07H021/04.

☐ 40. 5863538. 01 Jun 95; 26 Jan 99. Compositions for targeting the vasculature of solid tumors. Thorpe; Philip E., et al. 424/136.1; 424/138.1 424/141.1 424/154.1 424/155.1 424/172.1 424/173.1 424/174.1 424/181.1 530/387.3 530/387.7 530/388.22. A61K039/395 C12P021/08 C07K016/00.

☐ 41. 5855866. 02 Mar 94; 05 Jan 99. Methods for treating the vasculature of solid tumors. Thorpe; Philip E., et al. 424/1.49; 424/142.1 424/155.1 424/156.1 424/178.1 424/181.1 424/183.1 530/387.1 530/388.15 530/388.22 530/388.8 530/391.3 530/391.7 530/391.9. A61K051/10 A61K039/395 C07K016/00.

☐ 42. 5776427. 01 Jun 95; 07 Jul 98. Methods for targeting the vasculature of solid tumors. Thorpe; Philip E., et al. 424/1.49; 424/138.1 424/143.1 424/145.1 424/178.1 424/179.1 424/181.1 424/183.1 424/93.21 530/387.2 530/388.2 530/388.73 530/391.7. A61K051/10 A61K035/395 C07K016/00.

☐ 43. 5767254. 06 Jun 95; 16 Jun 98. Method for making amino acid glycosides and glycopeptides. Polt; Robin L.. 536/17.2; 530/322 530/327 530/328 530/329 530/330 530/331 536/17.9 536/18.5 562/575 564/165 564/197. C07H001/00 C07H015/00 C07K005/00 C07K007/00.

☐ 44. 5710134. 19 May 95; 20 Jan 98. Combination of necrosis-inducing substances with substances which are activated by necroses for the selective therapy of tumors and inflammatory disorders. Bosslet; Klaus, et al. 514/34; 536/6.4. A61K031/70.

☐ 45. 5693479. 13 Dec 94; 02 Dec 97. Fertility determination with transforming growth factor .beta.. Feinberg; Ronald F., et al. 435/7.21; 435/7.1 435/806 436/503 436/510 436/548 436/65 436/814 436/906 600/34. G01N033/567 G01N033/577.

☐ 46. 5650394. 04 Nov 93; 22 Jul 97. Use of urinastatin-like compounds to prevent premature delivery. Terao; Toshihiko, et al. 514/14; 424/682 424/709 424/94.4 435/7.1 435/7.4 435/7.9 435/7.91 435/7.92 435/7.93 435/7.94 435/7.95 514/192 514/195 514/198 514/2 514/200 514/209 514/21 514/24 514/29 514/420 514/61 514/653 514/8. A61K038/00 G01N033/53 G01N033/537 G01N033/543.

☐ 47. 5523229. 22 Mar 94; 04 Jun 96. Antibodies specific for oncofetal fibronectin. Feinberg; Ronald F., et al. 435/337; 435/344.1 435/7.2 530/380 530/387.1 530/388.1 530/388.25. C12N005/12 C07K016/18 C07K014/78 G01N033/53.

☐ 48. 5470949. 15 Dec 92; 28 Nov 95. Method for making amino acid glycosides and glycopeptides. Polt; Robin L.. 530/322; 530/327 530/328 530/329 530/330 530/331 562/575 564/165 564/197. A61K038/00 C07K005/00 C07K007/00 C07K017/00.

☐ 49. 5395825. 10 Mar 93; 07 Mar 95. Fertility regulation with transforming growth factor .beta.. Feinberg; Ronald F., et al. 514/21; 514/12 600/33 600/34. A61K037/02 A61B017/425 A61B017/435 A61D019/04.

☐ 50. 5300630. 02 Oct 92; 05 Apr 94. Oncofetal fibronectin epitope. Matsuura; Hidemitsu, et al. 530/329; 530/322. A61K037/02 C07K007/06.

Generate Collection | Print

Terms	Documents
(oncofetal or onco-fetal) near10 fibronectin	56

Prev Page Next Page Go to Doc#

Generate Collection | Print

Search Results - Record(s) 1 through 14 of 14 returned.

☐ 1. 20040014090. 05 Mar 03. 22 Jan 04. Encoded self-assembling chemical libraries (ESACHEL). Neri, Dario, et al. 435/6; 530/395 C12Q001/68 C07K014/00.

☐ 2. 20040013640. 10 Mar 03. 22 Jan 04. Compositions and methods for treatment of angiogenesis in pathological lesions. Zardi, Luciano, et al. 424/85.1; 424/145.1 424/85.2 424/85.5 A61K039/395 A61K038/21 A61K038/19 A61K038/20.

☐ 3. 20040001790. 03 Jan 03. 01 Jan 04. Methods for diagnosis and treatment of tumours. Hilger, Christoph-Stephan, et al. 424/1.69; 530/350 A61K051/00 C07K014/47.

☐ 4. 20030176663. 18 Dec 02. 18 Sep 03. Specific binding molecules for scintigraphy. Neri, Dario, et al. 530/388.22; 424/1.49 424/143.1 530/391.1 A61K051/00 A61K039/395 C07K016/30.

☐ 5. 20030045681. 28 Apr 99. 06 Mar 03. SPECIFIC BINDING MOLECULES FOR SCINTIGRAPHY, CONJUGATES CONTAINING THEM AND THERAPEUTIC METHOD FOR TREATMENT OF ANGIOGENESIS. NERI, DARIO, et al. 530/350; C07K001/00 C07K014/00 C07K017/00 C07K016/00 C12P021/08.

☐ 6. WO003055917A2. 02 Jan 03. 10 Jul 03. CONJUGATES COMPRISING AN ANTIBODY SPECIFIC FOR THE ED-B DOMAIN OF FIBRONECTIN AND THEIR USE FOR THE DETECTION AND TREATMENT OF TUMOURS. HILGER, CHRISTOPH-STEPAN, et al. C07K019/00; A61K047/48 A61K051/10 A61P035/00.

☐ 7. WO009958570A2. 11 May 99. 18 Nov 99. SPECIFIC BINDING MOLECULES FOR SCINTIGRAPHY, CONJUGATES CONTAINING THEM AND THERAPEUTIC METHOD FOR TREATMENT OF ANGIOGENESIS. NERI, DARIO, et al. C07K016/00;.

☐ 8. WO009745544A1. 23 May 97. 04 Dec 97. ANTIBODIES TO THE ED-B DOMAIN OF FIBRONECTIN, THEIR CONSTRUCTION AND USES. NERI, DARIO, et al. C12N015/13; C07K016/18 A61K039/395 C12N001/21 A61K051/10 G01N033/577 G01N033/68.

☐ 9. US20030176663A. New antibody, useful for preparing a composition for diagnosing or treating diseases characterized by vascular proliferation such as diabetic retinopathy, age-related macular degeneration or tumors. BIRCHLER, M, et al. A61K039/395 A61K051/00 C07K016/30.

☐ 10. WO2003055917A. Novel compound which comprises a peptide that is a derivative of recombinant scFv antibody L19 against the extra domain B of fibronectin, useful for binding a radioisotope, preferably 99mTc or 188Re. BERNDORFF, D, et al. A61K047/48 A61K047/488 A61K051/00 A61K051/10 A61K051/100 A61P035/00 A61P035/000 C07K014/47 C07K019/00.

☐ 11. WO 200162298A. Novel conjugate for treating lesions, comprises a specific binding member specific for extra-cellular matrix component present in lesions, and a molecule that exerts biocidal/cytotoxic effect on target cells in lesions. ARNEMOLLA, B, et al. A61K038/19 A61K038/20 A61K038/21 A61K039/395 A61K047/48 A61P009/00 A61P035/00 C07K014/525 C07K014/54 C07K014/57 C07K016/24.

☐ 12. WO 200162800A. An antibody, with specific affinity for a characteristic epitope of the ED-B domain of fibronectin for the treatment of diseases characterized by vascular proliferation. BIRCHLER, M, et al. A61K039/395 A61K051/00 A61K051/10 A61P027/02 A61P035/00 A61P043/00 C07C063/06 C07K016/18 G01N033/53 G01N033/574 G01N033/577.

☐ 13. WO 9958570A. Fibronectin ED-B domain epitope specific antibodies and conjugate antibodies. BIRCHLER, M, et al. A61K039/395 A61K047/48 A61K049/00 A61P035/00 C07K000/00 C07K001/00 C07K014/00 C07K016/00 C07K016/18 C07K017/00 C12N015/09 C12N015/13 C12P021/08 G01N033/574.

☐ 14. WO 9745544A. Binding member specific for ED-B oncofoetal domain of fibronectin - used for tumour diagnosis, and in tumour therapy. BALZA, E, et al. A01K051/10 A61K039/395 A61K051/10 A61P035/00 A61P043/00 C07K000/00 C07K016/18 C12N001/21 C12N015/09 C12N015/13 G01N033/577 G01N033/68.

Generate Collection Print

Terms	Documents
neri.in. and fibronectin	14

Prev Page Next Page Go to Doc#

First Hit

L1: Entry 1 of 14 File: PGPB Jan 22, 2004

PGPUB-DOCUMENT-NUMBER: 20040014090
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040014090 A1

TITLE: Encoded self-assembling chemical libraries (ESACHEL)

PUBLICATION-DATE: January 22, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Neri, Dario	Zurich		CH	
Melkko, Samu	Zurich		CH	

APPL-NO: 10/ 382107 [PALM]
DATE FILED: March 5, 2003

RELATED-US-APPL-DATA:
Application is a non-provisional-of-provisional application 60/362599, filed March 8, 2002,

FOREIGN-APPL-PRIORITY-DATA:

COUNTRY	APPL-NO	DOC-ID	APPL-DATE
WO	PCT/EP02/04153	2002WO-PCT/EP02/04153	April 15, 2002

INT-CL: [07] C12 Q 1/68, C07 K 14/00

US-CL-PUBLISHED: 435/6; 530/395
US-CL-CURRENT: 435/6; 530/395

REPRESENTATIVE-FIGURES: 1

ABSTRACT:

The invention concerns a chemical compound comprising a chemical moiety (p) capable of performing a binding interaction with a target molecule (e.g. a biological target) and further comprising an oligonucleotide (b) or functional analogue thereof. In a first embodiment according to the invention, the chemical compound is characterized in that the oligonucleotide (b) or functional analogue comprises at least one self-assembly sequence (b1) capable of performing a combination reaction with at least one self-assembly sequence (b1') of a complentary oligonucleotide or functional analogue bound to another chemical compound comprising a chemical moiety (q). In a second embodiment according to the invention, the chemical compound which comprises a coding sequence (b1) coding for the identification of the chemical moiety (p) is characterized in that the chemical compound further comprises at least one self-assembly moiety (m) capable of performing a combination reaction with at least one self-assembly moiety (m') of a similar chemical compound comprising a chemical moiety (q). The invention comprises corresponding libraries of chemical compounds as well as methods of biopanning of target molecules and of

identifying such targets.

ASSOCIATED APPLICATION DATA

[0001] This application claims priority of the U.S. Provisional Application No. 60/362,599 filed on Mar. 8, 2002 and of the international application PCT/EP 02/04153 filed on Apr. 15, 2002.

Search Results - Record(s) 1 through 12 of 12 returned.

☐ 1. 20030176663. 18 Dec 02. 18 Sep 03. Specific binding molecules for scintigraphy. Neri, Dario, et al. 530/388.22; 424/1.49 424/143.1 530/391.1 A61K051/00 A61K039/395 C07K016/30.

☐ 2. 20030045681. 28 Apr 99. 06 Mar 03. SPECIFIC BINDING MOLECULES FOR SCINTIGRAPHY, CONJUGATES CONTAINING THEM AND THERAPEUTIC METHOD FOR TREATMENT OF ANGIOGENESIS. NERI, DARIO, et al. 530/350; C07K001/00 C07K014/00 C07K017/00 C07K016/00 C12P021/08.

☐ 3. 6495673. 30 Oct 00; 17 Dec 02. Method for isolating the DNA encoding an enzyme. Neri; Dario, et al. 536/23.2; 435/188. C07H021/00 C07H021/04 C12N009/96.

☐ 4. 6184012. 22 Apr 99; 06 Feb 01. Isolation of enzymes. Neri; Dario, et al. 435/188; 435/183. C12N009/90 C12N009/00.

☐ 5. WO0009958570A2. 11 May 99. 18 Nov 99. SPECIFIC BINDING MOLECULES FOR SCINTIGRAPHY, CONJUGATES CONTAINING THEM AND THERAPEUTIC METHOD FOR TREATMENT OF ANGIOGENESIS. NERI, DARIO, et al. C07K016/00;.

☐ 6. WO009740141A2. 25 Apr 97. 30 Oct 97. ISOLATION OF ENZYMES. NERI, DARIO, et al. C12N009/00; C12N015/00 C12N015/62 C07K014/47.

☐ 7. US20030176663A. New antibody, useful for preparing a composition for diagnosing or treating diseases characterized by vascular proliferation such as diabetic retinopathy, age-related macular degeneration or tumors. BIRCHLER, M, et al. A61K039/395 A61K051/00 C07K016/30.

☐ 8. WO 200183816A. Detecting tumors including occult tumors in individual comprises amplifying nucleic acid of bodily fluid sample taken from individual to detect mRNA encoding extracellular matrix component. NERI, D, et al. C12Q001/68.

☐ 9. WO 200162800A. An antibody, with specific affinity for a characteristic epitope of the ED-B domain of fibronectin for the treatment of diseases characterized by vascular proliferation. BIRCHLER, M, et al. A61K039/395 A61K051/00 A61K051/10 A61P027/02 A61P035/00 A61P043/00 C07C063/06 C07K016/18 G01N033/53 G01N033/574 G01N033/577.

☐ 10. WO 9958570A. Fibronectin ED-B domain epitope specific antibodies and conjugate antibodies. BIRCHLER, M, et al. A61K039/395 A61K047/48 A61K049/00 A61P035/00 C07K000/00 C07K001/00 C07K014/00 C07K016/00 C07K016/18 C07K017/00 C12N015/09 C12N015/13 C12P021/08 G01N033/574.

☐ 11. WO 9942814A. Measurement of global carbon emissions from natural and anthropogenic sources. BIRCHLER, M, et al. A61K039/395 A61P035/00 C07K016/00 G01N021/35 G01N033/00.

☐ 12. US 6184012B. Isolating enzyme having desired activity - by linking enzyme to substrate, reacting to form product and isolating enzyme linked product. DEMARTIS, S, et al. C07H021/00 C07H021/04 C07K014/47 C12N009/00 C12N009/90 C12N009/96 C12N015/00 C12N015/09 C12N015/62.

Generate Collection Print

Terms	Documents
neri.in. and viti.in.	12

Prev Page Next Page Go to Doc#

First Hit

L3: Entry 1 of 56 File: PGPB Dec 30, 2004

DOCUMENT-IDENTIFIER: US 20040266025 A1
TITLE: Screening and treatment methods for prevention of preterm delivery

Summary of Invention Paragraph:
[0127] The antibodies can be raised and purified using methods known to those of skill in the art or obtained from publicly available sources. For example, monoclonal antibody FDC-6 (deposited at the American Type Culture Collection as accession number ATCC HB 9018; see, e.g., U.S. Pat. No. 4,894,326; see, also, Matsuura et al. (1985) Proc. Natl. Acad. Sci. U.S.A. 82:6517-6521; see, also, U.S. Pat. Nos. 4,919,889, 5,096,830, 5,185,270, 5,223,440, 5,236,846, 5,281,522, 5,468,619 and 5,516,702), which is raised against whole molecule onco-fetal fibronectin from a tumor cell line, can be used.

First Hit

L3: Entry 2 of 56 File: PGPB Dec 23, 2004

DOCUMENT-IDENTIFIER: US 20040260072 A1
TITLE: Hydrophilic, thiol-reactive cyanine dyes and conjugates thereof with biomolecules for fluorescence diagnosis

Summary of Invention Paragraph:
[0039] Thus known from the prior art are, e.g., antibodies that are directed against molecules that are expressed intensively in the angiogenetically active tissue and only to a very low level in the adjoining tissue (see WO 96/01653). Of special interest are antibodies that are against the receptors for vascular growth factors, receptors with endothelial cells to which inflammation mediators bind, and matrix proteins that are expressed specifically in the formation of new vessels. Preferred are other antibodies or antibody fragments that are directed against the matrix protein EDB-fibronectin and conjugates therefrom according to the invention. EDBfibronectin, also known as oncofetal fibronectin, is a splice variant of the fibronectin, which is formed specifically around newly formed vessels in the process of angiogenesis. Especially preferred are antibodies L19, E8, AP38 and AP39 against the EDB-fibronectin (Cancer Res 1999, 59,347; J Immunol Meth 1999, 231, 239; Protein Expr Purif 2001,21, 156).

DOCUMENT-IDENTIFIER: US 20040258747 A1
TITLE: Tumor-targeted drug delivery systems and uses thereof

Detail Description Paragraph:
[0087] In another specific embodiment, the NGR-containing molecule binds to oncofetal fibronectin. The expression of the oncofetal fragment of fibronectin (Fn-f) has also been found to be increased during angiogenesis and has been suggested as a marker of tumor angiogenesis. In one embodiment, the NGR-containing molecule is an antibody or fragment thereof to the oncofetal ED-B domain of fibronectin. The preparation of such an antibody and its conjugation with IL-12 is described in Halin et al (2002) Nature Biotechnology 20:264-269, which is incorporated by reference herein in its entirety.

DOCUMENT-IDENTIFIER: US 20040241752 A1
TITLE: Point of care diagnostic systems

Detail Description Paragraph:
[0128] The antibodies may be raised and purified using methods known to those of skill in the art or obtained from publicly available sources. For example, monoclonal antibody FDC-6 (deposited at the American Type Culture Collection as accession number ATCC HB 9018; see U.S. Pat. No. 4,894,326; see, also, Matsuura et al. (1985) Proc. Natl. Acad. Sci. U.S.A. 82:6517-6521; see, also, U.S. Pat. Nos. 4,919,889, 5,096,830, 5,185,270, 5,223,440, 5,236,846, 5,281,522, 5,468,619 and 5,516,702), which is raised against whole molecule onco-fetal fibronectin from a tumor cell line, may be used.

Detail Description Paragraph:
[0326] The antibody conjugated to the latex particles is mouse monoclonal antibody specific for fetal fibronectin. The antibody (FDC-6 or A137 monoclonal) is raised against whole molecule onco-fetal fibronectin from a tumor cell line. The antibody is produced as ascites at a contract manufacturer and is purified by Protein G and dialyzed into PBS buffer.

DOCUMENT-IDENTIFIER: US 20040214247 A1
TITLE: Novel fibronectin epitopes and proteinaceous molecules capable of binding said epitopes

Detail Description Paragraph:
[0102] Kaczmarek J, Castellani P, Nicolo G, Spina B, Allemanni G, Zardi L. Distribution of oncofetal fibronectin isoforms in normal, hyperplastic and neoplastic human breast tissues. Int J Cancer. Oct. 1, 1994;59(1):11-6.

Detail Description Paragraph:
[0105] Mandel U, Hamilton Therkildsen M, Reibel J, Sweeney B, Matsuura H, Hakomori S, Dabelsteen E, Clausen H. 1992. Cancer-associated changes in glycosylation of fibronectin. Immunohistological localization of oncofetal fibronectin defined by monoclonal antibodies. APMIS 100: 817-826.

Detail Description Paragraph:
[0107] Matsuura H, Hakomori S. 1985. The oncofetal domain of fibronectin defined by monoclonal antibody FDC-6: Its presence in fibronectins from fetal and tumor tissues and its absence in those from normal adult tissues and plasma. Proc. Natl. Acad. Sci. USA 82: 6517-6521.

Detail Description Paragraph:
[0108] Matsuura H, Takio K, Titani K, Greene T, Levery S B, Salyan M E K, Hakomori S. 1988. The oncofetal structure of human fibronectin defined by monoclonal antibody FDC-6. J. Biol. Chem. 263: 3314-3322.

Detail Description Paragraph:
[0109] Midulla M, Verma R, Pignatelli M, Ritter M A, Courtenay-Luck N S, George A J. Source of oncofetal ED-B-containing fibronectin: implications of production by both tumor and endothelial cells. Cancer Res. Jan. 1, 2000;60(1):164-9.

DOCUMENT-IDENTIFIER: US 20040072261 A1
TITLE: Method for the diagnosis and differential diagnosis of neurological diseases

Detail Description Paragraph:

[0392] Mariani G., Lasku A., Pau A., Villa G., Motta C., Calcagno G., Taddei G. Z., Castellani P., Syrigos K., Dorcaratto A., Epenetos A. A., Zardi L., Viale G. A. (1997) A pilot pharmacokinetic and immunoscintigraphic study with the technetium-99m labeled monoclonal antibody BC-1 directed against oncofetal fibronectin in patients with brain tumours. Cancer 15: 2484-2489.

First Hit

L3: Entry 13 of 56 File: PGPB May 8, 2003

DOCUMENT-IDENTIFIER: US 20030087318 A1
TITLE: Antibodies against an extracellular matrix complex and their use in the detection of cancer

Summary of Invention Paragraph:
[0005] Several studies have been direct toward identifying unique forms of extracellular matrix proteins associated with malignant tumor growth. For example, onco-fetal forms of collagen type I, fibronectin, and fibrinogen have been identified and characterized. However, such assays require solid tissue biopsy material and, therefore, are impractical to institute as a routine diagnostic assay.

DOCUMENT-IDENTIFIER: US 20020110833 A1
TITLE: Methods to diagnose a required regulation of trophoblast invasion

Detail Description Paragraph:
[0185] 27. Feinberg R F, Kilman H J, Locwood C J. 1991 Is oncofetal fibronectin a trophoblast glue for human implantation? Am. J. Pathol. 138: 537-543.

Detail Description Paragraph:
[0187] 29. Feinberg R F, Kliman H J, Wang C-L. 1994. Transforming growth factor-b stimulates trophoblast oncofetal fibronectin synthesis in vitro: implications for trophoblast implantation in vivo. J.Clin. Endocrinol Metab. 78: 1241-1248.

Detail Description Paragraph:
[0188] 30. Bischof P, Haenggeli L, and Campana A. 1995. Gelatinase and oncofetal fibronectin secretion is dependent on integrin expression on human cytotrophoblasts. Molecular Human Reproduction. 10: 734-742.